Replimune Group, Inc. (REPL)
| Market Cap | 405.43M -32.2% |
| Revenue (ttm) | n/a |
| Net Income | -314.85M |
| EPS | -3.44 |
| Shares Out | 82.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,957,749 |
| Open | 5.250 |
| Previous Close | 5.220 |
| Day's Range | 4.870 - 5.250 |
| 52-Week Range | 1.500 - 13.240 |
| Beta | 0.12 |
| Analysts | Sell |
| Price Target | 3.50 (-28.72%) |
| Earnings Date | Jun 5, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for REPL stock is "Sell." The 12-month stock price target is $3.5, which is a decrease of -28.72% from the latest price.
News
Replimune Group call volume above normal and directionally bullish
Bullish option flow detected in Replimune (REPL) Group with 7,813 calls trading, 1.3x expected, and implied vol increasing over 13 points to 147.17%. 6/5 weekly 8 calls and 6/5 weekly…
Replimune jumps on news FDA chief behind RP1 rejection may be removed
Shares of Replimune (REPL) are trading higher on Friday after The Wall Street Journal reported that President Trump has signed off on a plan to fire the Food and Drug…
FDA Commissioner Makary defends agency's decision on Replimune's drug
U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency's decision to not approve Replimune's drug for advanced skin cancer.
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's decision to not approve Replimune's drug for advanced skin cancer, saying it w...
Replimune rises after Wall Street Journal editorial defending RP1
In an opinion article, The Wall Street Journal’s The Editorial Board argued that the Food and Drug Administration’s rejection of Replimune’s (REPL) RP1 melanoma therapy contradicts both expert opinion...
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.
Replimune downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Replimune (REPL) to Neutral from Outperform with a price target of $2, down from $19, after the FDA issued a second complete response letter for the company’s BLA…
Replimune downgraded to Market Perform from Outperform at Leerink
Leerink analyst Jonathan Chang downgraded Replimune (REPL) to Market Perform from Outperform with a price target of $2, down from $11. The FDA has issued a Complete Response Letter regarding…
Replimune downgraded to Sell from Buy at H.C. Wainwright
H.C. Wainwright analyst Robert Burns double downgraded Replimune (REPL) to Sell from Buy without a price target after the FDA issued another complete response letter for RP1 plus Opdivo in…
Replimune downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama downgraded Replimune (REPL) to Underweight from Neutral without a price target after the company received another complete response letter from the FDA for RP1 plus nivolu...
Replimune downgraded to Hold from Buy at Jefferies
Jefferies downgraded Replimune (REPL) to Hold from Buy with a price target of $2, down from $13. The firm sees a “tough road ahead” for the company after RP1’s complete…
Replimune downgraded to Underperform from Market Perform at BMO Capital
BMO Capital downgraded Replimune (REPL) to Underperform from Market Perform with a price target of $1, down from $11. The FDA’s Complete Response Letter for RP1 lays bare the lack…
Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald downgraded Replimune (REPL) to Neutral from Overweight. The firm noted the FDA has issued a second complete response letter for RP1 plus nivolumab in advanced...
Replimune says FDA’s CRL for RP1 ‘disappointing’
Replimune (REPL) Group announced that the company received a complete response letter from the U.S. Food and Drug Administration for the Company’s Biologics License Application for RP1 in combination ...
Replimune says FDA ‘appears to have contradicted their positions’ in CRL
Replimune (REPL) said, “With the CRL, the company learned that a different review team was appointed for the resubmission and replaced the prior team who had interacted with the company.
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Replimune (REPL) to Neutral from Overweight.
Replimune downgraded to Neutral at Piper Sandler after second CRL
Piper Sandler downgraded Replimune (REPL) to Neutral from Overweight with a price target of $4, down from $14, after the FDA issued a second rejection of RP1 in second-line melanoma…
Replimune downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Replimune (REPL) to Neutral from Overweight with a $4 price target
US FDA declines to approve Replimune's drug for advanced skin cancer
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, the regulator said.
Replimune Group Transcript: Leerink Global Healthcare Conference 2026
The company is preparing for an April 10th PDUFA for its lead asset RP1 in advanced melanoma, with strong physician and patient advocacy support and commercial readiness in place. RP2 and additional indications are advancing, with key data expected by early next year. Cash runway extends into early 2027.
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Group Quarterly report: Q3 2026
Replimune Group has published its Q3 2026 quarterly earnings report on February 3, 2026.
Replimune Group Earnings release: Q3 2026
Replimune Group released its Q3 2026 earnings on February 3, 2026, summarizing the period's financial results.